CSL Behring Submits FDA Approval for Long Acting Hemophilia B Product

December 16, 2014

CSL Behring announced on Tuesday, December 16, 2014 that it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). Once approved by the FDA, rIX-FP (Coagulation Factor IX {Recombinant}, Albumin […]

FDA Approves Biogen Idec’s ELOCATE鈩, First Long Lasting Hemophilia A Therapy

June 6, 2014

鈥 Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days 鈥 鈥 Approval of Biogen Idec鈥檚 Second Innovative Hemophilia Therapy with Prolonged Circulation This Year 鈥 Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved ELOCTATE鈩 [Antihemophilic Factor (Recombinant), Fc Fusion Protein] […]

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.